Shares of Kura Oncology Inc (NASDAQ:KURA) have earned a consensus recommendation of “Buy” from the eight brokerages that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating and seven have given a buy rating to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $30.33.
KURA has been the topic of several analyst reports. HC Wainwright reiterated a “buy” rating and set a $31.00 price target on shares of Kura Oncology in a report on Monday, December 3rd. Piper Jaffray Companies set a $25.00 price objective on shares of Kura Oncology and gave the company a “buy” rating in a report on Monday, December 3rd. BidaskClub upgraded shares of Kura Oncology from a “hold” rating to a “buy” rating in a report on Friday, December 21st. Zacks Investment Research lowered shares of Kura Oncology from a “hold” rating to a “sell” rating in a report on Tuesday, January 8th. Finally, ValuEngine lowered shares of Kura Oncology from a “strong-buy” rating to a “buy” rating in a report on Thursday, January 24th.
NASDAQ KURA opened at $16.59 on Friday. Kura Oncology has a 52 week low of $10.20 and a 52 week high of $22.00. The company has a debt-to-equity ratio of 0.05, a quick ratio of 13.31 and a current ratio of 13.31. The firm has a market cap of $625.61 million, a PE ratio of -9.65 and a beta of 2.90.
Institutional investors and hedge funds have recently modified their holdings of the stock. Great West Life Assurance Co. Can acquired a new position in Kura Oncology in the 4th quarter valued at about $62,000. Legal & General Group Plc grew its position in Kura Oncology by 21.7% in the 4th quarter. Legal & General Group Plc now owns 5,175 shares of the company’s stock valued at $73,000 after acquiring an additional 923 shares in the last quarter. Metropolitan Life Insurance Co. NY grew its position in Kura Oncology by 403.3% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 9,638 shares of the company’s stock valued at $135,000 after acquiring an additional 7,723 shares in the last quarter. BlueMountain Capital Management LLC grew its position in Kura Oncology by 2,315.9% in the 3rd quarter. BlueMountain Capital Management LLC now owns 10,775 shares of the company’s stock valued at $189,000 after acquiring an additional 10,329 shares in the last quarter. Finally, Trexquant Investment LP acquired a new position in Kura Oncology in the 3rd quarter valued at about $217,000. Hedge funds and other institutional investors own 84.95% of the company’s stock.
Kura Oncology Company Profile
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.
Recommended Story: Asset Allocation Models, Which is Right For You?
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.